Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00309816 · ClinicalTrials.gov registry record · Phase 3

Study of Sildenafil in Patient With Heart Failure.

A Phase 3 study, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 3
Development phase
40
Enrollment target

NCT00309816: Completed Phase 3 study, sponsored by Massachusetts General Hospital.

NCT00309816 is a Phase 3 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00309816, a Phase 3 study, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 3
Development phase
40 participants
Enrollment target

Study Summary

The purpose of this study is to determine if sildenafil (Viagra) improves exercise tolerance.

Interventions

  • DRUG sildenafil

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2001-12
Est. Completion 2006-02
Phase Phase 3

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT00309816

The ClinicalTrials.gov registry entry for NCT00309816 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which sildenafil is the first listed.

NCT00309816 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00309816 about?

NCT00309816 is a clinical study titled "Study of Sildenafil in Patient With Heart Failure.". The purpose of this study is to determine if sildenafil (Viagra) improves exercise tolerance.

What is the current status of trial NCT00309816?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2001-12. Estimated completion is 2006-02.

What interventions are being tested in trial NCT00309816?

The interventions under investigation include: sildenafil (DRUG).

Who is sponsoring clinical trial NCT00309816?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.